Inc. magazine ranked Meridian Clinical Research as 2,938 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Omaha, NE, Meridian is a multi-specialty site network with 24 sites nationwide.
“It’s an honor to be recognized,” said Nicole Osborn, Meridian founder and CEO. “Our goal has always been to grow sustainably by partnering with leading physicians to drive high quality research.”
The company’s ranking reflects growth from 2016 to 2019, but Osborn said 2020 has been Meridian’s most remarkable year yet. Earlier this year, principal investigators at Meridian were the first to enroll patients into Phase II and III COVID-19 vaccine studies in the U.S. Two weeks ago, leaders of the Operation Warp Speed (OWS) program — including Moncef Slaoui, chief advisor, and General Gustave F. Perna, chief operating officer — visited Meridian’s internal medicine site in Savannah, GA.
Meridian has long been a leader in vaccine clinical trials, and is currently conducting COVID-19 vaccine studies in: Georgia (Savannah), Louisiana (Baton Rouge), Maryland (Rockville), Nebraska (Grand Island, Norfolk, Omaha), New York (Binghamton, Endwell), and South Dakota (Dakota Dunes).
“Our communities and patients are the core of our business,” said Osborn. “As COVID-19 afflicts the communities we serve, we have an opportunity and a responsibility to engage and educate as many people as possible about clinical research. We encourage anyone interested in clinical research to visit our website or call us.”
In 2019, Osborn launched a novel employee bonus program that ties annual bonuses to a charitable giving budget. As a result, Meridian donated more than $290,000 to people in need, fundraisers, and charitable organizations last year. Its 2020 goal is $360,000.
Complete results of the Inc. 5000 list, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at inc.com/inc5000. Sponsors and CROs interested in partnering with Meridian should email Andrew Kimball, VP, business development, at firstname.lastname@example.org.
About Meridian Clinical Research
Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty site network headquartered at its dedicated research center in Omaha, NE, and conducts Phase I-IV studies at investigative sites across North America. Meridian supports research across numerous therapeutic areas and specializes in high-volume vaccine trials.
More about Inc. and the Inc. 5000; Methodology
The 2020 Inc. 5000 is ranked according to percentage revenue growth when comparing 2016 and 2019. To qualify, companies must have been founded and generating revenue by March 31, 2016. They had to be U.S.-based, privately held, for profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2019. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2016 is $100,000; the minimum for 2019 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Companies on the Inc. 500 are featured in Inc.’s September issue. They represent the top tier of the Inc. 5000, which can be found at http://www.inc.com/inc5000
Meridian Clinical Research